NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader

Title

NewAmsterdam Shares Compelling Pooled Phase 3 Data for Obicetrapib; C4 Therapeutics Pursues Partners for Solid Tumor Degrader

NewAmsterdam Pharma has reported positive pooled data from three pivotal Phase 3 trials—BROOKLYN, BROADWAY, and TANDEM—evaluating obicetrapib, an oral, non-statin cholesterol-lowering drug targeted at patients with cardiovascular disease (CVD) whose LDL-C is not adequately controlled by existing therapies5.
Obicetrapib demonstrated durable and robust reductions in LDL-C (low-density lipoprotein cholesterol) and substantial lowering of lipoprotein(a) [Lp(a)], with pooled BROADWAY data showing a 45% reduction in Lp(a) levels2 5.
The safety profile of obicetrapib across these trials was comparable to placebo, supporting its clinical potential and regulatory advancement5.
NewAmsterdam expects to share additional data in 2025, including the impact on major adverse cardiac events (MACE) and outcomes from the ongoing PREVAIL cardiovascular outcomes trial4 5.
Submission to the European Medicines Agency (EMA) by partner Menarini is anticipated in the second half of 20255.
The company ended 2024 with $834.2 million in cash and equivalents, signaling strong financial backing for further development and regulatory processes5.
In parallel, C4 Therapeutics is actively seeking development partners to advance its solid tumor protein degrader programs, aiming to expand its pipeline and clinical reach (no direct details in these search results; general context inferred).